214 related articles for article (PubMed ID: 32932401)
1. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial.
Black DR; Minkin MJ; Graham S; Bernick B; Mirkin S
Menopause; 2020 Sep; 28(1):32-39. PubMed ID: 32932401
[TBL] [Abstract][Full Text] [Related]
2. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
[TBL] [Abstract][Full Text] [Related]
3. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
4. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
[No Abstract] [Full Text] [Related]
6. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
[TBL] [Abstract][Full Text] [Related]
7. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
[TBL] [Abstract][Full Text] [Related]
8. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
9. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
[TBL] [Abstract][Full Text] [Related]
10. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
[TBL] [Abstract][Full Text] [Related]
11. Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.
McClung MR; Kagan R; Graham S; Bernick B; Mirkin S; Constantine G
Menopause; 2022 Feb; 29(3):304-308. PubMed ID: 35213517
[TBL] [Abstract][Full Text] [Related]
12. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
Archer DF; Bernick BA; Mirkin S
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
[No Abstract] [Full Text] [Related]
13. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
White WB; Pitt B; Preston RA; Hanes V
Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
[TBL] [Abstract][Full Text] [Related]
14. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
16. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women.
Seely EW; Walsh BW; Gerhard MD; Williams GH
Hypertension; 1999 May; 33(5):1190-4. PubMed ID: 10334810
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
[TBL] [Abstract][Full Text] [Related]
18. A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
Thurman A; Hull ML; Stuckey B; Hatheway J; Zack N; Mauck C; Friend D
Menopause; 2023 Aug; 30(8):817-823. PubMed ID: 37339390
[TBL] [Abstract][Full Text] [Related]
19. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.
Thurman A; Hull ML; Stuckey B; Hatheway J; Zack N; Mauck C; Friend D
Menopause; 2023 Sep; 30(9):940-946. PubMed ID: 37625088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
